Review article: the gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans.

Hawkey, C J; Jackson, L; Harper, S E; Simon, T J; Mortensen, E; Lines, C R

Hawkey, C J; Jackson, L; Harper, S E; Simon, T J; Mortensen, E; Lines, C R.

Affiliation

Hawkey CJ; Department of Gastroenterology, University Hospital, Queen's Medical Centre, Nottingham, UK. cj.hawkey@nottingham.ac.uk

Aliment Pharmacol Ther ; 15(1): 1-9, 2001 Jan.

Article in En | MEDLINE | ID: mdl-11136272

Subject(s)

Cyclooxygenase Inhibitors/adverse effects; Digestive System/drug effects; Enzyme Inhibitors/adverse effects; Lactones/adverse effects; Prostaglandin-Endoperoxide Synthases/drug effects; Anti-Inflammatory Agents, Non-Steroidal/adverse effects; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Humans; Intestinal Perforation/chemically induced; Isoenzymes/drug effects; Membrane Proteins; Osteoarthritis/drug therapy; Peptic Ulcer/chemically induced; Sulfones

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Cyclooxygenase Inhibitors / Prostaglandin-Endoperoxide Synthases / Digestive System / Enzyme Inhibitors / Lactones Type of study: Clinical_trials Limits: Humans Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2001 Type: Article Affiliation country: United kingdom

Search on Google

XML

PubMed Links